Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds and APIs
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
MedImmune
September 22, 2016
Bubble stocks top the takeover premium charts
August 24, 2016
Few M&A teams venture beyond domestic borders
May 13, 2016
Payday approaches for Melinta's backers
October 20, 2015
Interview – Karolinska focuses, but not on early-stage medtech
September 18, 2015
Buying in growth beats innovation for pharma
June 30, 2015
Celgene goes for broke
November 05, 2014
Definiens shines a light on growing importance of biomarkers
June 19, 2014
Astra makes quiet progress with respiratory pipeline
June 18, 2014
Pfizer partners with Cellectis, but why not buy the company?
April 07, 2014
Daiichi’s ill-timed Indian foray ends in minority Sunbaxy stake
January 14, 2014
Merck catches Bristol with surprise PD-1 filing
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
September 03, 2021
Biopharma and Medtech Half-Year Review 2021
May 27, 2021
Evaluate Vantage Biopharma and Venture Capital: A Deep Dive
Editor's Picks
September 13, 2021
Esmo 2021 – Mirati bids to be belle of the ball
September 03, 2021
World Lung 2021 preview – China challenges and tremelimumab rises
September 07, 2021
Roche U-turns and Adaptimmune wins
September 02, 2021
Tecentriq pullout dominates the latest PD-(L)1 moves
September 06, 2021
Another gene therapy safety scare hits
